nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

12.04.2023 | Original Article

Testosterone or dihydrotestosterone: what should be evaluated in hirsutism?

verfasst von: Abbas Darjani, Narges Alizadeh, Kaveh Gharaei Nejad, Hojat Eftekhari, Rana Rafiei, Hasan Kazemi, Elahe Rafiei

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dihydrotestosterone is a more potent androgen derived from testosterone and androstenediones, but its measurement has not been routinely recommended in women with hirsutism, and there is limited information in this regard with equivocal findings. This study aimed to evaluate serum dihydrotestosterone level in patients with hirsutism compared to women without hirsutism.

Methods

In this case–control study (during 2021–2022), serum levels of total testosterone, free testosterone, and dihydrotestosterone were evaluated in 101 women with hirsutism and 101 healthy women. Hormonal levels were measured with chemiluminescent immunoassay method. Age and hormonal levels in each group, body mass index, menstrual status, complaint of decreased scalp hair density, and ovarian ultrasound findings in hirsutism group were collected and analyzed.

Results

There was significant difference in free testosterone and dihydrotestosterone levels (P < 0.001) and no significant difference in total testosterone level between two groups (P = 0.628). Dihydrotestosterone level was significantly higher in women with hirsutism with menses irregularity, complaint of decreased scalp hair density, and presence of polycystic ovary on ultrasound (P < 0.05).

Conclusions

Measuring dihydrotestosterone level is not considered in routine evaluation of hirsutism, but we think that this significant difference shows that elevated level of dihydrotestosterone hormone in women with hirsutism is an important factor.

Azarchi S, Bienenfeld A, Lo Sicco K et al (2019) Androgens in women. J Am Acad Dermatol 80(6):1509–1521. https://doi.org/10.1016/j.jaad.2018.08.061CrossRefPubMed

Mihailidis J, Dermesropian R, Taxel P et al (2017) Endocrine evaluation of hirsutism. Int J Women’s Dermatol 3(1):S6–S10. https://doi.org/10.1016/j.ijwd.2017.02.007CrossRef

Tahvilian R, Ebrahimi A, Beiki O et al (2015) Preparation and clinical evaluation of finasteride gel in the treatment of idiopathic Hirsutism. J Drug Assess 4(1):12–18. https://doi.org/10.3109/21556660.2015.1056525CrossRefPubMedPubMedCentral

Pasquali R, Gambineri A (2014) Therapy of endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol 170(2):R75–R90. https://doi.org/10.1530/eje-13-0585CrossRefPubMed

Swerdloff RS, Dudley RE, Page ST et al (2017) Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels. Endocr Rev 38(3):220–254. https://doi.org/10.1210/er.2016-1067CrossRefPubMedPubMedCentral

Burger HG (2002) Hormonal changes in the menopause transition. Recent Prog Horm Res 57(1):257–275. https://doi.org/10.1210/rp.57.1.257CrossRefPubMed

Cussen L, McDonnell T, Bennett G et al (2022) Approach to androgen excess in women: clinical and biochemical insights. Clin Endocrinol. https://doi.org/10.1111/cen.14710

Wu C, Wei K, Jiang Z (2017) 5α-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 15(1). https://doi.org/10.1186/s12958-017-0242-9

Münzker J, Hofer D, Trummer C et al (2015) Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J Clin Endocrinol Metab 100(2):653–660. https://doi.org/10.1210/jc.2014-2523CrossRefPubMed

10.

Azziz R, Carmina E, Sawaya ME (2000) Idiopathic hirsutism*. Endocr Rev 21(4):347–362. https://doi.org/10.1210/edrv.21.4.0401CrossRefPubMed

11.

Urysiak-Czubatka I, Kmieć ML, Broniarczyk-Dyła G (2014) Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Adv Dermatol Allergol 4:207–215. https://doi.org/10.5114/pdia.2014.40925CrossRef

12.

Osuka S, Nakanishi N, Murase T et al (2018) Animal models of polycystic ovary syndrome: a review of hormone-induced rodent models focused on hypothalamus-pituitary-ovary axis and neuropeptides. Reprod Med Biol 18(2):151–160. https://doi.org/10.1002/rmb2.12262CrossRefPubMedPubMedCentral

13.

Zhao H, Song X, Zhang L et al (2018) Comparison of androgen levels, endocrine and metabolic indices, and clinical findings in women with polycystic ovary syndrome in uygur and han ethnic groups from Xinjiang Province in China. Med Sci Monit 24:6774–6780. https://doi.org/10.12659/msm.909715CrossRefPubMedPubMedCentral

14.

Pankajakshan A, Pavithran PV, Menon AS et al (2017) Polycystic ovarian syndrome and hyperandrogenism: insights from a South Indian cohort. Indian J Endocrinol Metabol 2:21

15.

Minooee S, Ramezani Tehrani F, Azizi F (2015) Hirsutism region and the likelihood of metabolic syndrome: is there a link? Endocrine 53(2):607–609. https://doi.org/10.1007/s12020-015-0820-6CrossRefPubMed

16.

de Kroon RWPM, den Heijer M, Heijboer AC (2022) Is idiopathic hirsutism idiopathic? Clin Chim Acta 531:17–24. https://doi.org/10.1016/j.cca.2022.03.011CrossRefPubMed

17.

Diri H, Bayram F, Simsek Y (2015) Does finasteride, as well as metformin, improve insulin resistance in PCOS? Endocr Abstr. https://doi.org/10.1530/endoabs.37.gp.06.06

18.

Alizadeh N, Ayyoubi S, Naghipour M et al (2017) Can laser treatment improve quality of life of women with hirsutism? Int J Women’s Health 9:777–780. https://doi.org/10.2147/ijwh.s137910CrossRef

19.

Al Khalifah RA, Florez ID, Zoratti MJ et al (2020) Efficacy of treatments for polycystic ovarian syndrome management in adolescents. J Endocr Soc 5(1). https://doi.org/10.1210/jendso/bvaa155

Titel: Testosterone or dihydrotestosterone: what should be evaluated in hirsutism?
verfasst von: Abbas Darjani
Narges Alizadeh
Kaveh Gharaei Nejad
Hojat Eftekhari
Rana Rafiei
Hasan Kazemi
Elahe Rafiei
Publikationsdatum: 12.04.2023
Verlag: Springer International Publishing
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 6/2023
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-023-03366-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Testosterone or dihydrotestosterone: what should be evaluated in hirsutism?